Relapse of chronic phase chronic myeloid leukemia (CML) on imatinib: BCR-ABL kinase domain mutations conferring drug resistance are frequently detectable prior to clinical evidence of relapse.

被引：0
|
作者：
Shah, NP [1 ]
Nicoll, JM [1 ]
Paquette, RL [1 ]
Sawyers, CL [1 ]
机构：
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90024 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1418
引用
收藏
页码：366A / 366A
页数：1
相关论文
共 50 条
  • [41] MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations
    Yap, E.
    Norziha, Z. A.
    Simbun, A.
    Tumian, N. R.
    Cheong, S. K.
    Leong, C. F.
    Wong, C. L.
    LEUKEMIA RESEARCH, 2017, 59 : 32 - 40
  • [42] Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
    Agirre, X
    Fontalba, A
    Andreu, EJ
    Odero, MD
    Larróyoz, MJ
    Montiel, C
    Calasanz, M
    Fernández-Luna, JL
    Prósper, F
    HAEMATOLOGICA, 2003, 88 (12) : 1425 - 1426
  • [43] Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I:: Looking into the future of controlling drug resistance in chronic myeloid leukemia
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S120 - S130
  • [44] Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions
    Markose, Preetha
    Chendamarai, Ezhilarasi
    Balasubramanian, Poonkuzhali
    Velayudhan, Shaji Ramachandran
    Srivastava, Vivi M.
    Mathews, Vikram
    George, Biju
    Viswabandya, Auro
    Srivastava, Alok
    Chandy, Mammen
    LEUKEMIA & LYMPHOMA, 2009, 50 (12) : 2092 - 2095
  • [45] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
    Hasanova, Aypara
    Asadov, Chingiz
    Karimova, Nigar
    Shirinova, Aytan
    Aliyeva, Gunay
    Alimirzoyeva, Zohra
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [46] Early detection of imminent Hematologic relapse due to BCR-ABL kinase domain mutations in CML patients on imatinib therapy by D-HPLC.
    Ernst, T
    Erben, P
    Schenk, T
    Mueller, MC
    Emig, M
    Kreil, S
    La Rosée, P
    Berger, U
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2005, 106 (11) : 317A - 317A
  • [47] Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
    Leder, Kevin
    Foo, Jasmine
    Skaggs, Brian
    Gorre, Mercedes
    Sawyers, Charles L.
    Michor, Franziska
    PLOS ONE, 2011, 6 (11):
  • [48] Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
    Verma, Dushyant
    Fava, Carmen
    Kantarjian, Hagop
    Cortes, Jorge
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (04) : 256 - 257
  • [49] In early-chronic phase chronic myeloid leukemia patients treated with imatinib, resistance is rarely mediated by Abl kinase domain mutations
    Soverini, Simona
    Gnani, Alessandra
    Colarossi, Sabrina
    Castagnetti, Fausto
    Abruzzese, Efisabetta
    Merante, Serena
    Breccia, Massimo
    Capucci, Adele
    Specchia, Giorgina
    Radaelli, Franca
    Palandri, Francesca
    Poerio, Angela
    Iacobucci, Ilaria
    Amabile, Marilina
    Rosti, Gianantonio
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2007, 110 (11) : 574A - 574A
  • [50] HIGH RESOLUTION MELTING ANALYSIS FOR RAPID DETECTION OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH IMATINIB RESISTANCE
    Andrikovics, H.
    Meggyesi, N.
    Bors, A.
    Halm, G.
    Nahajevszky, S.
    Lueff, S.
    Batai, A.
    Remenyi, P.
    Masszi, T.
    Tordai, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 490 - 490
12345